lintuzumab
matuzumab
dacetuzumab
risankizumab
besilesomab
-lim-
extramelanopsin
tetrastatin
acrixolimab
brodalumab
melanophoric
spesolimab
olaratumab
pidilizumab
immunocompatible
tislelizumab
gevokizumab
brolucizumab
melanodermic
ravulizumab
ozoralizumab
muromonab
samalizumab
sibrotuzumab
inotuzumab ozogamicin
abagovomab
cibisatamab
melanoproteinase
melanotically
patritumab
carlumab
antinucleotide
pancytokeratin
-gov-
indatuximab ravtansine
panitumumab
heterophile
antinucleosome
lucatumumab
agonistic monoclonal antibody
antimelanogenic
drozitumab
melanocytotoxic
tebentafusp
tremelimumab
votumumab
olendalizumab
hypermelanosis
tisotumab
dalotuzumab